Trial · NCT04545554
Results by group489
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 489
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Observed Serum Concentration (Cmax) of Romosozumab | Cohort 1: Romosozumab Dose A (12 to < 18 Years of Age) | Day 1 | 2.64 | Standard Deviation 1.06 | μg/mL |
| Maximum Observed Serum Concentration (Cmax) of Romosozumab | Cohort 2: Romosozumab Dose A (5 to < 12 Years of Age) | Day 1 | 1.74 | Standard Deviation 0.825 | μg/mL |
| Maximum Observed Serum Concentration (Cmax) of Romosozumab | Cohort 3: Romosozumab Dose B (12 to < 18 Years of Age) | Day 1 | 13.8 | Standard Deviation 6.32 | μg/mL |
| Maximum Observed Serum Concentration (Cmax) of Romosozumab | Cohort 4: Romosozumab Dose B (5 to < 12 Years of Age) | Day 1 | 10.3 | Standard Deviation 1.70 | μg/mL |
| Maximum Observed Serum Concentration (Cmax) of Romosozumab | Cohort 5: Romosozumab Dose C (12 to < 18 Years of Age) | Day 1 | 25.7 | Standard Deviation 3.02 | μg/mL |
| Maximum Observed Serum Concentration (Cmax) of Romosozumab | Cohort 6: Romosozumab Dose C (5 to < 12 Years of Age) | Day 1 | 21.3 | Standard Deviation 6.45 | μg/mL |
| Maximum Observed Serum Concentration (Cmax) of Romosozumab | Cohort 1: Romosozumab Dose A (12 to < 18 Years of Age) | Day 57 | 2.43 | Standard Deviation 1.36 | μg/mL |
| Maximum Observed Serum Concentration (Cmax) of Romosozumab | Cohort 2: Romosozumab Dose A (5 to < 12 Years of Age) | Day 57 | 5.55 | Standard Deviation 2.11 | μg/mL |
| Maximum Observed Serum Concentration (Cmax) of Romosozumab | Cohort 3: Romosozumab Dose B (12 to < 18 Years of Age) | Day 57 | 12.8 | Standard Deviation 6.31 | μg/mL |
| Maximum Observed Serum Concentration (Cmax) of Romosozumab | Cohort 4: Romosozumab Dose B (5 to < 12 Years of Age) | Day 57 | 9.14 | Standard Deviation 7.50 | μg/mL |
| Maximum Observed Serum Concentration (Cmax) of Romosozumab | Cohort 5: Romosozumab Dose C (12 to < 18 Years of Age) | Day 57 | 22.8 | Standard Deviation 10.5 | μg/mL |
| Maximum Observed Serum Concentration (Cmax) of Romosozumab | Cohort 6: Romosozumab Dose C (5 to < 12 Years of Age) | Day 57 | 19.4 | Standard Deviation 2.14 | μg/mL |
| Time to Cmax (Tmax) of Romosozumab | Cohort 1: Romosozumab Dose A (12 to < 18 Years of Age) | Day 1 | 6.5 | Full Range 5.9 to 7.9 | day |
| Time to Cmax (Tmax) of Romosozumab | Cohort 2: Romosozumab Dose A (5 to < 12 Years of Age) | Day 1 | 7.9 | Full Range 7.9 to 15 | day |
| Time to Cmax (Tmax) of Romosozumab | Cohort 3: Romosozumab Dose B (12 to < 18 Years of Age) | Day 1 | 6.9 | Full Range 6.9 to 7.0 | day |
| Time to Cmax (Tmax) of Romosozumab | Cohort 4: Romosozumab Dose B (5 to < 12 Years of Age) | Day 1 | 6.9 | Full Range 4.9 to 7.1 | day |
| Time to Cmax (Tmax) of Romosozumab | Cohort 5: Romosozumab Dose C (12 to < 18 Years of Age) | Day 1 | 7.0 | Full Range 4.9 to 8.0 | day |
| Time to Cmax (Tmax) of Romosozumab | Cohort 6: Romosozumab Dose C (5 to < 12 Years of Age) | Day 1 | 7.5 | Full Range 6.9 to 8.9 | day |
| Time to Cmax (Tmax) of Romosozumab | Cohort 1: Romosozumab Dose A (12 to < 18 Years of Age) | Day 57 | 7.0 | Full Range 7.0 to 12 | day |
| Time to Cmax (Tmax) of Romosozumab | Cohort 2: Romosozumab Dose A (5 to < 12 Years of Age) | Day 57 | 7.0 | Full Range 6.9 to 7.0 | day |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04545554/results